Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Respir Cell Mol Biol ; 40(5): 620-30, 2009 May.
Article in English | MEDLINE | ID: mdl-18978304

ABSTRACT

Secretoglobin (SCGB) 3A1 and 3A2 are members of the small molecular weight secretoglobin gene superfamily. SCGB3A1 is a tumor suppressor gene, whereas SCGB3A2 has anti-inflammatory properties. Both genes are mainly expressed in the lung and trachea in mice. Whether the expression and/or function of these two genes are related is not known. Here we show that the expression of SCGB3A1 and SCGB3A2 are bidirectionally regulated by oncostatin M (OSM) when examined in a mouse transformed Clara cell line (mtCC); SCGB3A1 is up-regulated by OSM, while SCGB3A2 is down-regulated in a time- and dose-dependent manner. OSM-activated STAT3/5, through binding to the STAT-binding element located at -201 to -209 bp in the mouse Scgb3a1 gene promoter, and the extracellular signal-regulated kinase (ERK)- and p38-mitogen-activated protein kinase (MAPK) pathways are responsible for the OSM-induced up-regulation of SCGB3A1 expression. On the other hand, the -113 to -273 bp region in the Scgb3a2 promoter appears to be responsible for the OSM induced down-regulation of the gene. No significant differences in the levels or patterns of specific DNA-binding proteins were found in the -113 to -273 bp region as determined by electrophoretic mobility shift assays. Neither the ERK- nor p38-MAPK pathways were involved in the OSM-induced reduction of Scgb3a2 promoter activity. These results suggest that OSM-induced suppression of SCGB3A2 expression is an indirect effect of OSM. Expression of the Clara cell marker, CYP2F2, was markedly decreased upon OSM treatment in parallel with the decrease of SCGB3A2 expression in mtCC cells. The differential regulation of Scgb3a1 and Scgb3a2 gene expression by OSM may explain the unique functions of these genes in the lung.


Subject(s)
Gene Expression Regulation/drug effects , Oncostatin M/pharmacology , Proteins/genetics , Animals , Base Sequence , MAP Kinase Signaling System/drug effects , Mice , Mice, Inbred C57BL , Molecular Sequence Data , NIH 3T3 Cells , Oncostatin M/administration & dosage , Phenotype , Protein Binding/drug effects , Proteins/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Respiratory System/metabolism , Respiratory System/pathology , Response Elements/genetics , STAT Transcription Factors/metabolism , Secretoglobins
2.
Immunol Lett ; 97(1): 123-9, 2005 Feb 15.
Article in English | MEDLINE | ID: mdl-15626484

ABSTRACT

Airway inflammation is thought to play a major role in the pathogenesis of bronchial asthma. The precise role of individual inflammatory cells, mediator and asthma related genes in allergic lung diseases is not completely understood. The uteroglobin-related protein (UGRP) 1 was proposed to be an asthma candidate gene and play a role in regulating lung inflammation, however its precise function in the airways remains obscure. In this investigation, we used a mouse model of allergic airway inflammation to establish a relationship between UGRP 1 and IL-5 in airway inflammation. Ovalbumin (OVA) challenged mice demonstrate eosinophilia in airway tissues and high levels of IL-5 in bronchoalveolar lavage (BAL) fluid analogous to that found in bronchial asthma. Interestingly, these "OVA-challenged" mice show down-regulation of Ugrp1 expression as compared with the control group. Regression analysis further demonstrates a significant negative correlation between Ugrp1 mRNA expression in the lung and IL-5 levels in BAL fluid with r = 0.948 and P < 0.0001 when IL-5 levels were normalized by log transformation. Intranasal instillation of IL-5 to mice revealed an inhibitory effect of IL-5 on the expression of Ugrp1 mRNA. Together, these results indicate an involvement of IL-5 in the down-regulation of Ugrp1 expression in airway inflammation such as allergic asthma disease.


Subject(s)
Carrier Proteins/metabolism , Hypersensitivity/metabolism , Interleukin-5/metabolism , Proteins/metabolism , RNA, Messenger , Respiratory System/metabolism , Administration, Intranasal , Animals , Carrier Proteins/genetics , Female , Gene Expression/drug effects , Interleukin-5/administration & dosage , Interleukin-5/genetics , Interleukin-5/pharmacology , Mice , Proteins/genetics , Secretoglobins , Uteroglobin
3.
J Biol Chem ; 279(52): 54358-68, 2004 Dec 24.
Article in English | MEDLINE | ID: mdl-15485815

ABSTRACT

UGRP1 is a downstream target gene for homeodomain transcription factor T/EBP/NKX2.1, which is predominantly expressed in lung epithelial cells, and may play an anti-inflammatory role in lung inflammation. To understand the role of UGRP1 in inflammation, its expression was investigated in relation to cytokine signaling. In vivo experiments using mouse embryonic lung organ culture and intranasal administration of interleukin (IL) 10 revealed that constitutive expression of Ugrp1 mRNA is enhanced by IL-10. Increase of protein levels was also demonstrated by immunohistochemistry using embryonic lungs. This IL-10 induction of Ugrp1 gene expression occurs at the transcriptional level when examined using mouse embryonic lung primary cultures. In human lung NCI-H441 cells that in contrast to mouse lung cells, do not exhibit constitutive expression of the gene, expression of the UGRP1 gene was induced in a rapid and stable fashion. Two T/EBP, but not STAT3, binding sites located in the human UGRP1 gene promoter are responsible for IL-10 induction of the UGRP1 gene as judged by transfection, gel shift, and chromatin immunoprecipitation analyses. The IL-10 receptor chains, IL-10R1 and IL-10R2, are expressed in H441 cells, however, STAT3 was only weakly activated upon IL-10 treatment. In contrast, STAT3 was strongly activated when the cells were treated with other cytokines such as IL-22 and interferon-beta but UGRP1 expression was not increased. Together these results demonstrate that IL-10 induces UGRP1 gene expression in lung epithelial cells through a T/EBP/NKX2.1-dependent pathway. The results further suggest that UGRP1 might be a target for IL-10 anti-inflammatory activities in the lung.


Subject(s)
Carrier Proteins/genetics , Interleukin-10/pharmacology , Lung/metabolism , Nuclear Proteins/physiology , Proteins/genetics , Transcription Factors/physiology , Adenocarcinoma , Animals , Base Sequence , Binding Sites , Carrier Proteins/analysis , DNA/chemistry , DNA/metabolism , DNA-Binding Proteins/metabolism , Embryo, Mammalian , Epithelial Cells/chemistry , Epithelial Cells/metabolism , Gene Expression/drug effects , Humans , Immunohistochemistry , Lung/chemistry , Lung Neoplasms , Mice , Molecular Sequence Data , Mutagenesis , Nuclear Proteins/metabolism , Organ Culture Techniques , Promoter Regions, Genetic/genetics , Proteins/analysis , RNA, Messenger/analysis , Receptors, Interleukin/genetics , Receptors, Interleukin/physiology , Receptors, Interleukin-10 , STAT3 Transcription Factor , Secretoglobins , Thyroid Nuclear Factor 1 , Trans-Activators/metabolism , Transcription Factors/metabolism , Transfection , Tumor Cells, Cultured , Uteroglobin
SELECTION OF CITATIONS
SEARCH DETAIL
...